AbSci’s ABS-201: Promising AGA Treatment with Key Milestones Ahead
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Swayampakula Ramakanth maintains a Buy rating on AbSci's stock, citing the potential of its ABS-201 program for treating androgenetic alopecia. The program shows promising preclinical results and upcoming milestones, including a proof-of-concept readout in 2026. Ramakanth, a 5-star analyst, sees the stock as a compelling buy due to anticipated clinical milestones and current valuation. Needham also maintains a Buy rating with a $7.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments